The estimated Net Worth of Capital Fund Ii Cooperatief... is at least $13.2 Million dollars as of 23 April 2019. Capital Cooperatief owns over 53,571 units of Hookipa Pharma Inc stock worth over $13,169,233 and over the last 5 years Capital sold HOOK stock worth over $0.
Capital has made over 1 trades of the Hookipa Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 53,571 units of HOOK stock worth $749,994 on 23 April 2019.
The largest trade Capital's ever made was buying 53,571 units of Hookipa Pharma Inc stock on 23 April 2019 worth over $749,994. On average, Capital trades about 53,571 units every 0 days since 2019. As of 23 April 2019 Capital still owns at least 2,494,173 units of Hookipa Pharma Inc stock.
You can see the complete history of Capital Cooperatief stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro..., and Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: